HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme [letter]

E Florence, S De Wit, A Castagna, E Ribera, A Hill, H Vanaken, Y van Delft, S Marks

    Research output: Contribution to journalLetterpeer-review

    Original languageEnglish
    JournalInternational Journal of STD & AIDS
    Issue number3
    Pages (from-to)224-225
    Number of pages2
    Publication statusPublished - 2010


    • B780-tropical-medicine
    • Viral diseases
    • HIV
    • AIDS
    • HAART
    • Antiretrovirals
    • Etravirine
    • Darunavir
    • Ritonavir
    • Raltegravir
    • RNA suppression
    • CD4 lymphocyte count
    • Efficacy
    • Clinical trials

    Cite this